NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals. Its technology targets mitochondria and chloroplasts, two special cellular components that harbor their own DNA and are important to create energy for cells to grow. They are also critical for producing various biochemical molecules key to specific pathways and functions. NAPIGEN's genome technology has broad application in human and animal healthcare, agriculture, and industrial biotechnology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/12/22 | $7,850,000 | Seed |
Breakout Labs MARSBIO RA Capital Management  The Grantham Foundation Thiel Foundation Thrive SVG Ventures United Mitochondrial Disease Foundation | undisclosed |
